ScholarIQanswers from OpenAlex & ORCID
Masayuki Takeda
ResearcherPublications, citations & collaboration network
Masayuki Takeda is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Masayuki Takeda have?
ScholarIQindexed works
Masayuki Takeda has 707 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Masayuki Takeda have?
ScholarIQcitation count
Masayuki Takeda has 17,586 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Masayuki Takeda?
ScholarIQh-index
Masayuki Takeda has an h-index of 66 in OpenAlex.
What is the i10-index of Masayuki Takeda?
ScholarIQi10-index
Masayuki Takeda has an i10-index of 253 in OpenAlex.
What is the ORCID of Masayuki Takeda?
ScholarIQorcid
The ORCID for Masayuki Takeda is on the source record.
What is the OpenAlex record for Masayuki Takeda?
ScholarIQopenalex
The OpenAlex for Masayuki Takeda is on the source record.
What are the most-cited papers on Masayuki Takeda?
ScholarIQmost cited works
6th International Consultation on Incontinence. Recommendations of the International Scientific Committee: EVALUATION AND TREATMENT OF URINARY INCONTINENCE, PELVIC ORGAN PROLAPSE AND FAECAL INCONTINENCE
Paul Abrams, Karl‐Erik Andersson, Apostolos Apostolidis, Lori A. Birder, Donna Z. Bliss, Linda Brubaker, Linda Cardozo, David Castro‐Díaz, P. R. O’Connell, Alan Cottenden, Nikki Cotterill, Dirk De Ridder, Roger R. Dmochowski, Chantale Dumoulin, Mandy Fader, Christopher Fry, Howard B. Goldman, Philip M. Hanno, Yukio Homma, Vik Khullar, Christopher Maher, Ian Milsom, Diane K. Newman, Rien J.M. Nijman, Kevin Rademakers, Dudley Robinson, Peter Rosier, Eric Rovner, Stefano Salvatore, Masayuki Takeda, Adrian Wagg, Todd H. Wagner, Alan Wein
Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score
Yukio Homma, Masaki Yoshida, Narihito Seki, Osamu Yokoyama, Hidehiro Κakizaki, Momokazu Gotoh, Tomonori Yamanishi, Osamu Yamaguchi, Masayuki Takeda, Osamu Nishizawa
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis Paz‐Ares, Suresh S. Ramalingam, Tudor–Eliade Ciuleanu, Jong-Seok Lee, László Urbán, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Clarisse Audigier-Valette, Jacobus A. Burgers, Adam Płużański, Randeep Sangha, Carlos Gallardo, Masayuki Takeda, Helena Linardou, Lorena Lupinacci, Ki Hyeong Lee, Claudia Caserta, Mariano Provencio, Enric Carcereny, Gregory A. Otterson, Michael Schenker, Bogdan Żurawski, Aurelia Alexandru, A. Vergnenègre, Judith Raimbourg, Kynan Feeney, Sang‐We Kim, Hossein Borghaei, Kenneth J. O’Byrne, Matthew D. Hellmann, Arteid Memaj, Faith E. Nathan, Judith Bushong, Phuong Tran, Julie R. Brahmer, Martin Reck